Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Medtronic PLC (MDT) vs Mesoblast Limited (MESO) Price & Performance

Medtronic PLCTrade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

Medtronic PLC vs Mesoblast Limited — how do they compare? Medtronic PLC trades at $89.59 (market cap $116.07B), while Mesoblast Limited trades at $16.87 (market cap $2.21B). The key difference: Medtronic PLC is far larger — about 52.5× Mesoblast Limited's market cap, and Medtronic PLC pays a 3.18% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.

MDTMESO
Market Cap
$116.07B$2.21B
Sector
HealthTechnology
52-Week High
$105.35$20.96
52-Week Low
$73.75$12.88
Enterprise Value
$134.82B$2.21B
Dividend Yield
3.18%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Medtronic PLC

Medtronic (MDT) trades at $89.41, up 2.58% on the day, reflecting positive momentum. The stock exhibits bullish technical signals with strong moving average support and a consensus analyst price target of $98.75. Fundamentally, the company reported revenue of $33.54B for 2025 with a net income margin of 13.2%, and has consistently beaten EPS estimates in recent quarters. Recent news highlights institutional acquisitions and positive developments in medical technology platforms.

The outlook for MDT is positive, driven by earnings beats, robust cash flow, and growth in cardiac and robotic surgery segments. Key opportunities include undervaluation relative to analyst targets and dividend stability. Risks involve rising debt levels and competitive pressures in the medtech sector. The stock presents a compelling case for growth-oriented income investors.

Mesoblast Limited

MESO trades at $16.9, up 1.32% on the day, with a bullish technical signal from moving averages. The company reported Ryoncil net revenues of $36 million for the quarter ended June 30, 2026, and achieved its target of 300 patients in a Phase 3 trial for chronic low back pain. Despite strong revenue growth from its commercial launch, fundamentals show a net income margin of -144.33% and negative EBITDA of $80.06 million for 2025, reflecting significant losses amid expansion.

The outlook hinges on commercial execution and regulatory progress, with analyst consensus leaning buy (45% buy ratings). Key risks include high cash burn, dependence on pipeline success, and competitive pressures. Upside potential exists if revenue growth accelerates and losses narrow, but investors face volatility from clinical trial outcomes and funding needs.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Medtronic PLC

One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.

Read more on MDT

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO